Please login to the form below

Not currently logged in
Email:
Password:

Santen

This page shows the latest Santen news and features for those working in and with pharma, biotech and healthcare.

AbbVie's 'The Story of HS' wins at PMEA 2016

AbbVie's 'The Story of HS' wins at PMEA 2016

off competition from Novartis, Santen UK and Tillotts Pharma UK.

Latest news

  • NICE no for new eye disease drug NICE no for new eye disease drug

    NICE's preliminary recommendation has been to ask Santen Pharmaceutical for more information on Ikervis (ciclosporin) for treating severe keratitis in adults with dry eye disease which has not improved despite

  • Antibiotics among 7 new drugs backed by EMA Antibiotics among 7 new drugs backed by EMA

    The final two drugs to feature in the list of positive opinions were Santen's Ikervis (ciclosporin) for the treatment of the eye condition severe keratitis and MDCO's Raplixa (human

  • Meeting with resistance

    Low-grade B-cell lymphoma; mantle cell lymphoma. Japan. Diquafosol. Diquas Ophthalmic Solution 3% (Santen Pharmaceutical).

  • Inspire drops cystic fibrosis programme

    net sales of Diquas (diquafosol) for dry eye, which is marketed in Japan by Santen but has not been approved in the US.

  • Thin on the ground

    UK. Dorzolamide/timolol. Cosopt (Santen Pharmaceutical Co). Glaucoma and ocular hypertension. Japan.

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Ophthalmology. Ophthalmology is dominated by a small number of the same therapies marketed by different companies in different regions; Regeneron, Bayer and Santen all market Eylea, whereas Novartis and Roche market

  • Deal Watch table for May 2014 Deal Watch table for May 2014

    653. Merck &Co / Santen. Asset / product acquisition. 2. Ophthalmology products in Japan, Europe and Asia Pacific with sales of $400m.

  • Pharma deals during May 2014 Pharma deals during May 2014

    Not content with the Bayer deals, Merck &Co also divested its ophthalmic business (mainly Timolol) in Japan, Asia Pacific and Europe to its licensee Santen.

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    22. Tracon Pharmaceuticals/ Santen Pharmaceutical Co. Licence. Tracon's anti‐endoglin antibodies, including TRC105 for wet AMD (p2).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Luis Iglesias heads Santen EMEA Luis Iglesias heads Santen EMEA

    His promotion sees him succeed Shigeo Taniuchi. Luis Iglesias has been promoted as Santen’s EMEA head, a move that sees him succeed Shigeo Taniuchi - who returns to Japan to become ... Iglesias initially joined Santen in 2017 as its senior vice

  • Paolo Casati named as general manager of Santen Italy Paolo Casati named as general manager of Santen Italy

    Has over 30 years of experience in the sector. Eye care specialist Santen Pharma has appointed Paolo Casati as general manager of its Italian subsidiary. ... I am very excited to join the team to establish Santen Italy as one of the major companies of

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics